<DOC>
	<DOCNO>NCT00615823</DOCNO>
	<brief_summary>Clinical effect tolerability atorvastatin versus placebo patient Pulmonary Hypertension : double-blinded , randomise , prospective phase II study 6 month adjust dos Atorvastatin</brief_summary>
	<brief_title>Atorvastatin Pulmonary Hypertension</brief_title>
	<detailed_description>PAH characterize dyspnea , fatigue , low extremity edema result heart failure . Several research prove inflammation may participate pathogenesis PAH . As atorvastatin inhibits inflammation beneficial effect blood vessel type cardiovascular disease . Therefore , atorvastatin may similarly benefit patient PAH . Experimental data suggest statins attenuates pulmonary hypertension animal experiment . In addition , non-controlled clinical study suggest atorvastatin effective safe patient pulmonary hypertension . Participants study randomly assign receive 6 month daily placebo tablet daily atorvastatin double-blind fashion . The study compare safety efficacy placebo atorvastatin .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Able understand willing sign inform consent form &lt; =65 &gt; =18years old Diagnosis pulmonary arterial hypertension ( Mean pulmonary artery pressure great 25 mm Hg rest pulmonary capillary wedge pressure le 15 mm Hg ) ) idiopathic , b ) familial , c ) associate connectivetissue disease , ) congenital systemictopulmonary shunt occur surgical/interventional repair perform least five year previously absence indication surgery/intervention treatment e ) chronic thromboembolism PAH absence indication surgery Patients WHO functional class II III Vasodilator Testing nonresponders Baseline sixminute walk distance 100 460 PAH related etiology ( Groups 2 , 3 5 pulmonary hypertension ) A forced expiratory volume one second/ force vital capacity bellow 50 % total lung capacity le 60 percent predict value A 6minute walk distance less 100 460 A positive acute vasodilator response Current treatment calciumchannel blocker specific therapy ( endothelin receptor antagonist , phosphodiesterase5 inhibitor , prostacyclin ) Inability perform 6minute walk test Serum transaminase level three time upper limit normal Creatine kinase level five time upper limit normal Previously diagnose heart disease serious cardiac arrhythmia , unstable angina pectoris , myocardial infarction History transient ischemia attack stroke within three month Bleeding disorder Positive pregnancy test breastfeeding practice History suspicion inability cooperate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>